The FDA has granted traditional approval to tisotumab vedotin-tftv (Tivdak, Seagen [now part of Pfizer]) for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tisotumab vedotin-tftv previously received accelerated approval for this indication.
Efficacy was evaluated in innovaTV 301 (ClinicalTrials.gov. Identifier NCT04697628), a multicenter, open-label, active-controlled randomized trial that enrolled 502 patients with recurrent or metastatic
MAY 1, 2024